

Role of the clinician


- **At general level**

- Understand and explain experience on new regimens to policy makers: local and national
 - Do they understand the disease and its epidemiology?
- Inform data for pharmaco-economic evaluation and clinical utilization – national level
- Inform how will data be applied in the clinic?
- Address the specific barriers hindering the accessibility of new regimens in clinical practice
- Evaluate impact of early access programs
- Provide education and training for practitioners

- **Hospital level**

- Ensure adequate resources for patients care
 - Provide optimal care for specific groups
-

Making sense of the NHS



Providing access for patients

- How can the high cure rates seen in clinical trials translate into day-to-day practice?
 - What barriers does the treating physician face in obtaining access
 - And how can they be overcome?
 - What are the expectations of
 - Patients
 - Physicians
 - The pharmaceutical industry
 - The Payers
 - The regulators
 - What measures to ensure value added pricing are in place?
 - How do we scale up testing and treatment?
-

Hurdles to access

- Efforts to accomplish access face significant hurdles
 - High cost drugs: implementation delayed in some countries
 - Boxed into prioritization strategies?
 - Improved diagnosis:
 - Are there efforts to widen screening?
 - How are the less informed or those with social deprivation being treated?
 - What efforts are being made for PWID and incarcerated?
 - Prejudicial attitudes?
-

What are payers seeking?

Have clear goals been defined?

- To prevent transmission of incident infection in at risk groups
 - To prevent progression to clinical disease
 - Is treatment being scaled up with eradication in mind?
 - Is task shifting being planned to shift care to primary health?

 - Or

 - Are groups being prioritized to restrict use?
 - Only the sickest being treated?
 - Not recognising the need to treat all?
 - Are interferon, telaprevir, boceprevir still being advocated?
 - To limit the budget impact of new HCV drugs?
 - Regional variation imposed?
-

UK: Expanded access program

- Inclusion criteria
 - Chronic hepatitis C CPT score ≥ 7
 - Prior decompensation
 - Extrahepatic manifestations hepatitis C
 - End organ damage
 - Not included
 - Small HCC
 - Protease inhibitor failures with cirrhosis
 - Treatment
 - SOF + LDV
 - SOF + DCV
-